Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

This study demonstrates tolerability and durable clinical benefit of bortezomib when given at 1.5 mg/m2 biweekly. Despite a higher response rate in the biweekly arm, no major difference in patient's outcome was observed between the two arms in the final analysis.